Antibody

LifeLabs launches COVID-19 antibody test to help Canadians identify prior exposure to the Coronavirus

Medical specialties, Medicine, Clinical medicine, Occupational safety and health, Immunology, Coronavirus disease, Zoonoses, Antibody, HIV/AIDS, COVID-19 testing
Monday, November 23, 2020 - 5:30pm

However, it can help individuals and their health care providers understand if theyve had prior infection or exposure to COVID-19even if they were asymptomatic.

Key Points: 
  • However, it can help individuals and their health care providers understand if theyve had prior infection or exposure to COVID-19even if they were asymptomatic.
  • For the most accurate results (results with the highest sensitivity), it is recommended that the antibody test is ordered 3-4 weeks post-onset of symptoms or post-exposure.
  • Customers can visit any LifeLabs location with a signed requisition to get a blood sample collected for the antibody test.
  • For more information on steps to getting the COVID-19 antibody test, as well as FAQs about the test, process, and reviewing your results, visit our COVID-19 antibody test page on lifelabs.com.

Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies

Health, Clinical trials, General Health, Research, Pharmaceutical, Science, Physical sciences, Natural sciences, Chemistry, Immunology, Ligand Pharmaceuticals, Antibody, Ligand
Monday, November 23, 2020 - 1:30pm

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb discovery platform.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb discovery platform.
  • The progress by these companies resulted in a total of $4.5 million in milestone payments being earned by Ligand.
  • "We are very pleased with the progress and impressive data our partners are reporting with their Ligand OmniAb-derived antibodies," said John Higgins, Chief Executive Officer of Ligand.
  • Next year we anticipate the first two OmniAb-derived antibodies could receive regulatory approvals, and these events could start the first OmniAb royalty revenue to Ligand.

IPA Selects Polytope™ Formulations for Pre-Clinical Studies

Medical specialties, Medicine, Clinical medicine, Immunology, Immune system, Biotechnology, Monoclonal antibody, Antibody
Monday, November 23, 2020 - 12:00pm

The Company announced today that it has nominated the first cocktail consisting of four, human, synergistic antibodies to enter pre-clinical testing.

Key Points: 
  • The Company announced today that it has nominated the first cocktail consisting of four, human, synergistic antibodies to enter pre-clinical testing.
  • We did not sacrifice quality and we believe our approach is the suitable and effectual path."
  • Pre-clinical manufacturing of the fully human lead, 4-mAb candidates is underway, with the pre-clinical studies scheduled to launch in early January in the Netherlands.
  • IPA exploits multiple antibody formats, valency, and size to select antibodies against multiple/rare epitopes.

Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19

Medical specialties, Clinical medicine, Medicine, Immunology, Monoclonal antibodies, Biotechnology, Immune system, Coronavirus disease, Antibody, Antiviral drug, Cancer immunotherapy
Sunday, November 22, 2020 - 1:17am

The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated.

Key Points: 
  • The safety and effectiveness of this investigational therapy for use in the treatment of COVID-19 continues to be evaluated.
  • A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19.
  • Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system," said FDA Commissioner Stephen M. Hahn, M.D.
  • Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses.

XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail

Medical specialties, Health, Life sciences, Immunology, Immunity, Antibody, Influenza, Biopharmaceutical, Virus
Thursday, November 19, 2020 - 1:15pm

The Company continues to analyze components of its so-called FLUVID therapy as it develops manufacturing capability for a product candidate.

Key Points: 
  • The Company continues to analyze components of its so-called FLUVID therapy as it develops manufacturing capability for a product candidate.
  • Ongoing research has also found that the True Human antibodies in this therapeutic cocktail that target influenza are capable of rescuing 100% of animals that receive an otherwise lethal dose of flu virus.
  • XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies.
  • XBiotechs True Human antibodies are the only available antibodies derived without modification from humans who possess natural immunity to certain diseases.

Study Utilizing Imaging Mass Cytometry Details Changes in Lung Tissue Architecture at the Single-Cell Level in Patients with COVID-19

Branches of biology, Biology, Biomarkers, Cell biology, Clinical pathology, Laboratory techniques, Mass cytometry, IMC, Cytometry Part A, Stromal cell, Antibody, Branches of biology, Biology, Biomarkers, Cell biology, Clinical pathology, Laboratory techniques, Mass cytometry, IMC, Cytometry Part A, Stromal cell, Antibody
Thursday, November 19, 2020 - 1:32pm

This phenotype has been identified based on spatial analysis of lung tissue at the single-cell level throughout the disease continuum.

Key Points: 
  • This phenotype has been identified based on spatial analysis of lung tissue at the single-cell level throughout the disease continuum.
  • Results of the study , which have not yet been peer-reviewed, are available online through the medRxiv pre-print service.
  • This study utilized the Fluidigm reagents portfolio to label antibodies in a custom-designed panel of 36 biomarkers to capture different immune and stromal compartments of the lung.
  • Fluidigm, theFluidigmlogo, CyTOF, Hyperion, Imaging Mass Cytometry and IMC are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

Medical specialties, Health sciences, Life sciences, Immunology, Biotechnology, Genmab, Monoclonal antibody, Antibody, Bispecific monoclonal antibody, Therapy
Thursday, November 19, 2020 - 12:00pm

IPA willgenerate novel bispecific antibody combinations using Genmab's proprietary DuoBody platform and IPA's proprietary antibodies in the field of infectious disease.

Key Points: 
  • IPA willgenerate novel bispecific antibody combinations using Genmab's proprietary DuoBody platform and IPA's proprietary antibodies in the field of infectious disease.
  • "Partnering with Genmab aligns with IPA's mission to develop safe and effective therapies for patients, in this case, specifically pertaining to the growing demand in infectious disease," said Dr. Jennifer Bath, Chief Executive Officer of ImmunoPrecise Antibodies.
  • DuoBody technology has been successfully used in many Genmab internal or partnered investigational clinical therapies.
  • ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease.

Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial

Medical specialties, CD37, Hodgkin lymphoma, Clinical medicine, Antibody, Branches of biology
Thursday, November 19, 2020 - 6:43am

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

Key Points: 
  • Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
  • Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
  • Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.
  • This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial

Medical specialties, CD37, Hodgkin lymphoma, Clinical medicine, Antibody, Branches of biology
Thursday, November 19, 2020 - 6:41am

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

Key Points: 
  • Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
  • Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
  • Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.
  • This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

AbCellera Expands Technology Stack with Acquisition of Trianni for $90 Million

Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Biology, Branches of biology, Biotechnology, Immunology, Immune system, Glycoproteins, Monoclonal antibody, AbCellera, Transgene, Genetic engineering, Antibody
Wednesday, November 18, 2020 - 9:34pm

The acquisition deepens AbCelleras technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties.

Key Points: 
  • The acquisition deepens AbCelleras technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties.
  • With its technology and team, Trianni amplifies our capability to generate human antibodies and provides a strong foundation for developing increasingly powerful transgenic mouse technologies, said Carl Hansen, Ph.D., CEO of AbCellera.
  • Triannis lead technology, the Trianni Mouse, is a next-generation platform enabling efficient generation of diverse, fully-human monoclonal antibodies.
  • The Trianni transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic engineering technology.